Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 161

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 161
---
 Income and Expense - Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 –  The decrease in gain on sale of contingent payments was due to the sale of the Vorasidenib Royalty Rights in the three months ended September 30, 2024 discussed above in Overview. The decrease in milestone payment from gain on sale of oncology business was due to the receipt of the Vorasidenib Milestone Payment in the three months ended September 30, 2024 discussed above in Overview. 

Other Income and Expense - Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 –  The decrease in gain on sale of contingent payments was due to the sale of the Vorasidenib Royalty Rights in the nine months ended September 30, 2024 discussed above in Overview. The decrease in milestone payment from gain on sale of oncology business was due to the receipt of the Vorasidenib Milestone Payment in the nine months ended September 30, 2024 discussed above in Overview. The increase in interest income, net in the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 was primarily attributable to increased return on our investments. 

27

Net (Loss) IncomeThree Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Net (loss) income$(103,433)$947,915 $(304,742)$770,248 

Net (Loss) Income - Three Months Ended September 30, 2025 vs. Three Months Ended September 30, 2024 – The increase in net loss for the three months ended September 30, 2025 compared to the three months ended September 30, 2024 was primarily driven by the sale of the Vorasidenib Royalty Rights and the receipt of the Vorasidenib Milestone Payment in the three months ended September 30, 2024 discussed above in Overview, partially offset by the income tax expense in the three months ended September 30, 2024 as a result of the income related to the Vorasidenib Royalty Rights and Vorasidenib Milestone Payment.

Net (Loss) Income - Nine Months Ended September 30, 2025 vs. Nine Months Ended September 30, 2024 – The increase in net loss for the nine months ended September